TORONTO, March 5, 2015 /CNW/ - George Weston Limited (TSX: WN) ("GWL" or
the "Company") today announced its consolidated unaudited results for
the 13 weeks ended December 31, 2014 and the release of its 2014 Annual
Report. The Company's fourth quarter 2014 results include the results
of Shoppers Drug Mart Corporation ("Shoppers Drug Mart") as well as the
associated acquisition-related accounting adjustments.
The 2014 Annual Report includes the Company's audited annual
consolidated financial statements and Management's Discussion and
Analysis ("MD&A") for the fiscal year ended December 31, 2014. The 2014
Annual Report has been filed with SEDAR and is available at sedar.com and in the Investor Centre section of the Company's website at
weston.ca.
As a result of the Company's reporting calendar, the fourth quarter and
full year 2014 include an extra week of operations ("the 53rd week")
compared to 2013.
"2014 was a year of transformation for George Weston Limited as we
continued to grow and evolve our portfolio of businesses and strengthen
our competitive position. Loblaw's acquisition of Shoppers Drug Mart
creates a unique retail footprint while providing customers
best-in-class food and health and wellness offerings along with the
combined Company's trusted and most recognized brands, while focusing
on convenience and value", said W. Galen Weston, Executive Chairman,
George Weston Limited.
2014 FOURTH QUARTER HIGHLIGHTS
-
Sales of $11,734 million, an increase of $3,815 million or 48.2%.
-
Adjusted EBITDA(1) of $1,022 million, an increase of $468 million or 84.5%.
-
Adjusted operating income(1) of $736 million, an increase of $393 million or 114.6%.
-
Adjusted basic net earnings per common share(1) of $1.58, an increase of $0.60 or 61.2%.
-
Free cash flow(1) of $504 million for the fourth quarter and $1,033 million for full year
2014.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(unaudited)
For the periods ended
|
|
Dec. 31, 2014
|
|
|
|
Dec. 31, 2013(3)
|
|
|
|
|
|
|
Dec. 31, 2014
|
|
|
|
Dec. 31, 2013(3)
|
|
|
|
|
($ millions except where otherwise indicated)
|
|
(13 weeks)
|
|
|
|
(12 weeks)
|
|
Change
|
|
|
|
(53 weeks)
|
|
|
|
(52 weeks)
|
|
Change
|
|
|
Sales
|
|
$
|
11,734
|
|
|
|
$
|
7,919
|
|
48.2%
|
|
|
|
|
$
|
43,918
|
|
|
|
$
|
33,582
|
|
30.8%
|
|
|
|
Sales excluding Shoppers Drug Mart
|
|
$
|
8,680
|
|
|
|
$
|
7,919
|
|
9.6%
|
|
|
|
|
$
|
34,868
|
|
|
|
$
|
33,582
|
|
3.8%
|
|
|
EBITDA(1)
|
|
$
|
1,032
|
|
|
|
$
|
588
|
|
75.5%
|
|
|
|
|
$
|
2,515
|
|
|
|
$
|
2,507
|
|
0.3%
|
|
|
Adjusted EBITDA(1)
|
|
$
|
1,022
|
|
|
|
$
|
554
|
|
84.5%
|
|
|
|
|
$
|
3,539
|
|
|
|
$
|
2,420
|
|
46.2%
|
|
|
Adjusted EBITDA margin(1)
|
|
|
8.7%
|
|
|
|
|
7.0%
|
|
|
|
|
|
|
|
8.1%
|
|
|
|
|
7.2%
|
|
|
|
|
|
Adjusted EBITDA(1) excluding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shoppers Drug Mart
|
|
$
|
670
|
|
|
|
$
|
554
|
|
20.9%
|
|
|
|
|
$
|
2,551
|
|
|
|
$
|
2,420
|
|
5.4%
|
|
|
|
Adjusted EBITDA margin(1) excluding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shoppers Drug Mart
|
|
|
7.7%
|
|
|
|
|
7.0%
|
|
|
|
|
|
|
|
7.3%
|
|
|
|
|
7.2%
|
|
|
|
|
Operating income
|
|
$
|
622
|
|
|
|
$
|
376
|
|
65.4%
|
|
|
|
|
$
|
973
|
|
|
|
$
|
1,616
|
|
(39.8)%
|
|
|
Adjusted operating income(1)
|
|
$
|
736
|
|
|
|
$
|
343
|
|
114.6%
|
|
|
|
|
$
|
2,414
|
|
|
|
$
|
1,533
|
|
57.5%
|
|
|
Adjusted operating margin(1)
|
|
|
6.3%
|
|
|
|
|
4.3%
|
|
|
|
|
|
|
|
5.5%
|
|
|
|
|
4.6%
|
|
|
|
|
|
Adjusted operating income(1) excluding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shoppers Drug Mart
|
|
$
|
446
|
|
|
|
$
|
343
|
|
30.0%
|
|
|
|
|
$
|
1,630
|
|
|
|
$
|
1,533
|
|
6.3%
|
|
|
|
Adjusted operating margin(1) excluding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shoppers Drug Mart
|
|
|
5.1%
|
|
|
|
|
4.3%
|
|
|
|
|
|
|
|
4.7%
|
|
|
|
|
4.6%
|
|
|
|
|
Net earnings from continuing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
operations attributable to
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
shareholders of the Company
|
|
$
|
161
|
|
|
|
$
|
177
|
|
(9.0)%
|
|
|
|
|
$
|
126
|
|
|
|
$
|
614
|
|
(79.5)%
|
|
|
Adjusted net earnings from continuing
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
operations attributable to
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
shareholders of the Company(1)
|
|
$
|
212
|
|
|
|
$
|
135
|
|
57.0%
|
|
|
|
|
$
|
728
|
|
|
|
$
|
586
|
|
24.2%
|
|
|
Basic net earnings per common share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
from continuing operations ($)
|
|
$
|
1.18
|
|
|
|
$
|
1.31
|
|
(9.9)%
|
|
|
|
|
$
|
0.64
|
|
|
|
$
|
4.47
|
|
(85.7)%
|
|
|
Adjusted basic net earnings per common
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
share from continuing operations(1) ($)
|
|
$
|
1.58
|
|
|
|
$
|
0.98
|
|
61.2%
|
|
|
|
|
$
|
5.35
|
|
|
|
$
|
4.25
|
|
25.9%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pavi Binning, President, George Weston Limited, commented that "We are
pleased with George Weston Limited's fourth quarter results. Loblaw
delivered strong financial and operating performance in both core
grocery and pharmacy despite a highly competitive retail environment.
Weston Foods delivered volume growth across all business units.
Financial performance was comparable with the fourth quarter of 2013
which was in-line with expectations. Loblaw and Weston Foods will
continue to execute on their respective strategies in 2015 to drive
sustainable, long term growth and profitability".
GWL's fourth quarter 2014 adjusted basic net earnings per common share(1) increased to $1.58 from $0.98 in the same period in 2013. The
improvement of $0.60 was primarily due to an increase in Loblaw
Companies Limited ("Loblaw") earnings net of the dilution in the
Company's ownership as a result of shares issued by Loblaw to acquire
Shoppers Drug Mart. Loblaw earnings were positively impacted in the
fourth quarter of 2014 by Shoppers Drug Mart results, partially offset
by higher interest expense driven by the financing associated with the
acquisition of Shoppers Drug Mart and a higher adjusted income tax rate(1).
Basic net earnings per common share decreased by $0.13 to $1.18 compared
to the same period in 2013, and were impacted by the following
significant items:
-
the unfavourable year-over-year impact of the fair value adjustment of
the forward sale agreement for 9.6 million Loblaw common shares of $93
million ($0.56 per common share);
-
the amortization of the acquired Shoppers Drug Mart intangible assets of
$124 million ($0.33 per common share);
-
the negative impact of the recognition of the fair value increment on
the acquired Shoppers Drug Mart inventory sold of $69 million ($0.17
per common share); partially offset by
-
the favourable year-over-year impact of the restructuring of franchise
fees of $40 million ($0.11 per common share).
For a complete list of items which impacted basic net earnings per
common share but that are excluded from adjusted basic net earnings per
common share(1), see the "Non-GAAP Financial Measures" section of this News Release.
REPORTABLE OPERATING SEGMENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weston Foods
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(unaudited)
For the periods ended
|
|
Dec. 31, 2014
|
|
|
|
Dec. 31, 2013(3)
|
|
|
|
|
|
|
Dec. 31, 2014
|
|
|
|
Dec. 31, 2013(3)
|
|
|
|
|
($ millions except where otherwise indicated)
|
|
(13 weeks)
|
|
|
|
(12 weeks)
|
|
Change
|
|
|
|
|
(53 weeks)
|
|
|
|
(52 weeks)
|
|
Change
|
|
|
Sales
|
|
$
|
469
|
|
|
|
$
|
413
|
|
13.6%
|
|
|
|
|
$
|
1,923
|
|
|
|
$
|
1,812
|
|
6.1%
|
|
|
EBITDA(1)
|
|
$
|
91
|
|
|
|
$
|
56
|
|
62.5%
|
|
|
|
|
$
|
301
|
|
|
|
$
|
305
|
|
(1.3)%
|
|
|
Adjusted EBITDA(1)
|
|
$
|
74
|
|
|
|
$
|
67
|
|
10.4%
|
|
|
|
|
$
|
311
|
|
|
|
$
|
322
|
|
(3.4)%
|
|
|
Adjusted EBITDA margin(1)
|
|
|
15.8%
|
|
|
|
|
16.2%
|
|
|
|
|
|
|
|
16.2%
|
|
|
|
|
17.8%
|
|
|
|
|
Operating income
|
|
$
|
74
|
|
|
|
$
|
40
|
|
85.0%
|
|
|
|
|
$
|
231
|
|
|
|
$
|
238
|
|
(2.9)%
|
|
|
Adjusted operating income(1)
|
|
$
|
57
|
|
|
|
$
|
52
|
|
9.6%
|
|
|
|
|
$
|
241
|
|
|
|
$
|
259
|
|
(6.9)%
|
|
|
Adjusted operating margin(1)
|
|
|
12.2%
|
|
|
|
|
12.6%
|
|
|
|
|
|
|
|
12.5%
|
|
|
|
|
14.3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales Weston Foods sales for the fourth quarter of 2014 were $469 million, an
increase of $56 million or 13.6% compared to the same period in 2013.
Foreign currency translation and the 53rd week positively impacted
sales by approximately 4.1% and 7.3%, respectively. Excluding the
impact of foreign currency translation and the 53rd week, sales
increased by 2.2% due to an increase in volumes across all business
units, partially offset by the combined negative impact of pricing and
changes in sales mix.
EBITDA(1) Weston Foods EBITDA(1) in the fourth quarter of 2014 increased by $35 million to $91 million
compared to the same period in 2013. The increase was primarily driven
by insurance proceeds relating to a prior quarter inventory loss in the
net amount of $12 million and the year-over-year favourable impact of
the fair value adjustment of commodity derivatives of $11 million, each
of which is described in the "Non-GAAP Financial Measures" section of
this News Release. In addition, the increase was due to an improvement
in underlying operating performance described below.
Adjusted EBITDA(1) in the fourth quarter of 2014 was $74 million, an increase of
$7 million compared to the same period in 2013. Adjusted EBITDA margin(1) for 2014 decreased by 0.4% compared to the same period in 2013. The
increase in adjusted EBITDA(1) in the fourth quarter of 2014 was primarily due to the positive impact
of the 53rd week of $6 million. Excluding the 53rd week, adjusted
EBITDA(1) was relatively flat as higher volumes were offset by new plant costs.
Operating Income Weston Foods operating income for the fourth quarter of 2014 was $74
million, an increase of $34 million compared to the same period in 2013
and was positively impacted by the items described above in EBITDA(1).
Adjusted operating income(1) was $57 million in the fourth quarter of 2014, an increase of
$5 million compared to the same period in 2013, driven by the increase
in adjusted EBITDA(1) described above, partially offset by the increase in depreciation and
amortization in the fourth quarter of 2014 of $2 million due to the
investments in capital.
Loblaw
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(unaudited)
For the periods ended
|
|
Dec. 31, 2014
|
|
|
|
Dec. 31, 2013(3)
|
|
|
|
|
|
|
Dec. 31, 2014
|
|
|
|
Dec. 31, 2013(3)
|
|
|
|
|
($ millions except where otherwise indicated)
|
|
(13 weeks)
|
|
|
|
(12 weeks)
|
|
Change
|
|
|
|
|
(53 weeks)
|
|
|
|
(52 weeks)
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales
|
|
$
|
11,413
|
|
|
|
$
|
7,640
|
|
49.4%
|
|
|
|
|
$
|
42,611
|
|
|
|
$
|
32,371
|
|
31.6%
|
|
|
|
Sales excluding Shoppers Drug Mart
|
|
$
|
8,359
|
|
|
|
$
|
7,640
|
|
9.4%
|
|
|
|
|
$
|
33,561
|
|
|
|
$
|
32,371
|
|
3.7%
|
|
|
Retail gross profit
|
|
$
|
2,925
|
|
|
|
$
|
1,625
|
|
80.0%
|
|
|
|
|
$
|
9,734
|
|
|
|
$
|
6,961
|
|
39.8%
|
|
|
EBITDA(1)
|
|
$
|
898
|
|
|
|
$
|
490
|
|
83.3%
|
|
|
|
|
$
|
2,126
|
|
|
|
$
|
2,127
|
|
|
|
|
Adjusted EBITDA(1)
|
|
$
|
948
|
|
|
|
$
|
487
|
|
94.7%
|
|
|
|
|
$
|
3,228
|
|
|
|
$
|
2,098
|
|
53.9%
|
|
|
Adjusted EBITDA margin(1)
|
|
|
8.3%
|
|
|
|
|
6.4%
|
|
|
|
|
|
|
|
7.6%
|
|
|
|
|
6.5%
|
|
|
|
|
|
Adjusted EBITDA(1) excluding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shoppers Drug Mart
|
|
$
|
596
|
|
|
|
$
|
487
|
|
22.4%
|
|
|
|
|
$
|
2,240
|
|
|
|
$
|
2,098
|
|
6.8%
|
|
|
|
Adjusted EBITDA margin(1) excluding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shoppers Drug Mart
|
|
|
7.1%
|
|
|
|
|
6.4%
|
|
|
|
|
|
|
|
6.7%
|
|
|
|
|
6.5%
|
|
|
|
|
Operating income
|
|
$
|
505
|
|
|
|
$
|
294
|
|
71.8%
|
|
|
|
|
$
|
654
|
|
|
|
$
|
1,303
|
|
(49.8)%
|
|
|
Adjusted operating income(1)
|
|
$
|
679
|
|
|
|
$
|
291
|
|
133.3%
|
|
|
|
|
$
|
2,173
|
|
|
|
$
|
1,274
|
|
70.6%
|
|
|
Adjusted operating margin(1)
|
|
|
5.9%
|
|
|
|
|
3.8%
|
|
|
|
|
|
|
|
5.1%
|
|
|
|
|
3.9%
|
|
|
|
|
|
Adjusted operating income(1) excluding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shoppers Drug Mart
|
|
$
|
389
|
|
|
|
$
|
291
|
|
33.7%
|
|
|
|
|
$
|
1,389
|
|
|
|
$
|
1,274
|
|
9.0%
|
|
|
|
Adjusted operating margin(1) excluding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shoppers Drug Mart
|
|
|
4.7%
|
|
|
|
|
3.8%
|
|
|
|
|
|
|
|
4.1%
|
|
|
|
|
3.9%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales Loblaw sales in the fourth quarter of 2014 were $11.4 billion, an
increase of $3.8 billion compared to the same period in 2013, and
included $3.1 billion in sales related to Shoppers Drug Mart. Excluding
Shoppers Drug Mart and the 53rd week sales of $574 million, Retail
sales increased $117 million and same-store sales growth for core
grocery was 2.4% (2013 - 0.6%). Loblaw's average quarterly internal
food price index was slightly higher than (2013 - lower than) the
average quarterly national food price inflation of 3.5% (2013 - 0.9%)
as measured by "The Consumer Price Index for Food Purchased from
Stores". In the last twelve months, corporate and franchise store
square footage remained flat.
Gross Profit Loblaw's Retail gross profit increased by $1,300 million to
$2,925 million in the fourth quarter of 2014 from $1,625 million in the
same period in 2013. The increase included:
-
$1,221 million of gross profit generated by Shoppers Drug Mart;
partially offset by
-
the negative impact of the recognition of the fair value increment on
the acquired Shoppers Drug Mart inventory sold of $69 million.
Excluding the above impacts, Retail gross profit increased by
$148 million to $1,773 million in the fourth quarter of 2014 compared
to the same period in 2013, driven by higher sales, including the 53rd
week. Retail gross profit percentage remained flat at 21.9% compared to
2013, and was positively impacted by synergies related to the
acquisition of Shoppers Drug Mart and reductions in transportation
costs and was negatively impacted by increased shrink.
EBITDA(1) Loblaw EBITDA(1) was $898 million in the fourth quarter of 2014, an increase of $408
million, and was negatively impacted by a number of items, including
certain items relating to the acquisition of Shoppers Drug Mart,
partially offset by the restructuring of franchise fees of $40 million.
For a complete list of items that impacted EBITDA(1) but that are excluded from adjusted EBITDA(1), see the "Non-GAAP Financial Measures" section of this News Release.
Loblaw adjusted EBITDA(1) was $948 million in the fourth quarter of 2014, an increase of
$461 million compared to the same period in 2013, and included $352
million of adjusted EBITDA(1) related to Shoppers Drug Mart. Excluding Shoppers Drug Mart, adjusted
EBITDA(1) increased by $109 million, primarily driven by Retail including the
53rd week and net synergies. Excluding Shoppers Drug Mart, the 53rd week and net synergies, the
improvement in Retail adjusted EBITDA(1) was driven by the increase in gross profit described above, supply
chain efficiencies, changes in the fair value of Loblaw's franchise
investments and lower administrative and other operating costs,
partially offset by higher foreign exchange losses and higher
investments in Loblaw's franchise business. Excluding Shoppers Drug
Mart, adjusted EBITDA margin(1) was 7.1% compared to 6.4% in the same period in 2013.
Operating Income Loblaw operating income increased by $211 million to $505 million
compared to the fourth quarter of 2013, and was negatively impacted by
the items described above in EBITDA(1) and the amortization of intangible assets acquired with Shoppers Drug
Mart. For a complete list of items which impacted operating income but
that are excluded from adjusted operating income(1), see the "Non-GAAP Financial Measures" section of this News Release.
Adjusted operating income(1) was $679 million in the fourth quarter of 2014, an increase of
$388 million compared to the same period in 2013, and included $290
million of adjusted operating income(1) related to Shoppers Drug Mart. Excluding Shoppers Drug Mart, adjusted
operating income(1) increased by $98 million and was positively impacted by the improvement
in adjusted EBITDA(1) as described above, partially offset by an increase in depreciation and
amortization of $11 million.
NET INTEREST EXPENSE AND OTHER FINANCING CHARGES
In the fourth quarter of 2014, net interest expense and other financing
charges increased by $125 million to $231 million compared to the same
period in 2013, and included the unfavourable year-over-year impact of
the fair value adjustment of the forward sale agreement for 9.6 million
Loblaw common shares, as well as a number of other items. For
a complete list of the items that impacted net interest expense and
other financing charges but that are excluded from adjusted net
interest expense and other financing charges(1), see the "Non-GAAP Financial Measures" section of this News Release.
Adjusted net interest expense and other financing charges(1) in the fourth quarter of 2014 increased by $51 million, driven by
higher interest on long term debt, primarily as a result of debt
incurred by Loblaw to finance its acquisition of Shoppers Drug Mart.
INCOME TAXES
Income tax expense for the fourth quarter of 2014 was $95 million and
the effective income tax rate was 24.3%. Income tax expense for the
fourth quarter of 2013 was $51 million and the effective income tax
rate was 18.9%, which reflects an increase in certain non-taxable
amounts. The adjusted income tax expense(1) for the fourth quarter of 2014 was $155 million and the adjusted tax
rate(1) was 26.6%. The adjusted income tax expense(1) for the fourth quarter of 2013 was $45 million and the adjusted tax
rate(1) was 18.7%, which reflects an increase in certain non-taxable amounts.
ADJUSTED DEBT(1)
The Company's adjusted debt(1) increased significantly in 2014 as a result of Loblaw's acquisition of
Shoppers Drug Mart. On closing of the acquisition, adjusted debt(1) was $12.1 billion. The Company made significant progress in meeting its
debt reduction target and decreased adjusted debt(1) by approximately $400 million in the fourth quarter of 2014 and $700
million since the closing of the acquisition, resulting in an adjusted
debt(1) balance of $11.4 billion as at December 31, 2014. The reduction in
adjusted debt(1) since closing included the repayment of a $350 million medium term note
("MTN") at maturity and repayments under the unsecured term loan
facility (net of Choice Properties Real Estate Investment Trust's
("Choice Properties") notes issued to third parties), partially offset
by the issuance of a $200 million MTN and other indebtedness.
FREE CASH FLOW(1)
The Company's free cash flow(1) increased by $149 million to $504 million in the fourth quarter of
2014. The year-over-year increase in the fourth quarter of 2014 was
primarily due to higher cash earnings driven by Shoppers Drug Mart,
partially offset by increased capital investments as well as higher
interest payments.
ACQUISITION OF SHOPPERS DRUG MART CORPORATION
In the fourth quarter of 2014, Loblaw realized net synergies of
approximately $49 million generated primarily from improved cost of
inventories sold and from purchasing efficiencies in goods not for
resale. The net synergies realized, year-to-date, were $101 million.
Loblaw continues to expect to achieve annualized synergies of
$300 million in the third full year following the close of the
acquisition of Shoppers Drug Mart (net of related costs).
Pursuant to a Consent Agreement reached with the Competition Bureau in
2014, Loblaw was required to divest 16 Shoppers Drug Mart stores, two
franchise grocery stores and nine in-store pharmacy operations.
In the fourth quarter of 2014, 11 Shoppers Drug Mart stores were sold
which resulted in a divestiture loss of $14 million to Loblaw recorded
in operating income. On a year-to-date basis, two franchise grocery
stores and 13 Shoppers Drug Mart stores were sold, and nine in-store
pharmacies were licensed to unrelated parties which resulted in a net
divestiture loss of $12 million to Loblaw recorded in operating income.
The final three Shoppers Drug Mart stores were approved for sale by the
Competition Bureau and were sold subsequent to the end of 2014 for
estimated proceeds of $9 million.
As a result of the acquisition, GWL's ownership interest in Loblaw
decreased from approximately 63% to approximately 46%. The Company
remains the controlling shareholder and continues to consolidate
Loblaw.
OUTLOOK(2)
This outlook reflects the underlying operating performance of the
Company's reportable operating segments as discussed below.
Weston Foods expects a decline in adjusted operating income(1) in 2015 that is greater than that experienced in 2014 on an equivalent
52-week basis. Management remains committed to continuing to drive long
term financial performance in Weston Foods and expects to make capital
investments of approximately $300 million in targeted areas of growth
as well as incremental investments in innovation and capabilities. The
costs associated with this level of capital and other investments as
well as higher input costs will be partially offset by pricing, volume
growth and productivity. The decline in adjusted operating income(1) is expected to be greater in the first half of the year.
Loblaw's strategic framework is focused on delivering the best in food,
best in health and beauty, operational excellence and growth. This
strategic framework is supported by a financial strategy of maintaining
a stable trading environment which targets positive same-store sales
and stable gross margin; surfacing efficiencies; delivering synergies
as a result of its acquisition of Shoppers Drug Mart; and deleveraging
the balance sheet.
On a full year comparative basis, reflecting 2014 financial results for
Loblaw and Shoppers Drug Mart, in 2015 Loblaw expects to:
-
maintain positive same-store sales and stable gross margin (excluding
synergies) in its Retail segment;
-
achieve net synergies as result of the acquisition of Shoppers Drug Mart
approaching $200 million;
-
continue to drive net efficiencies across the core grocery business by
achieving reductions in supply chain, administrative functions and
information technology ("IT"), while still investing in key areas, like
eCommerce;
-
grow adjusted operating income(1) in its core grocery business, excluding synergies;
-
experience a decline in adjusted operating income(1) in its core pharmacy business, excluding synergies, as a result of
investments in key projects and other factors;
-
grow consolidated adjusted net earnings(1) (including synergies) relative to 2014, with adjusted basic net
earnings per common share(1) being moderated due to a significantly increased weighted average share
count;
-
target a capital expenditure program of approximately $1.2 billion; and
-
remain on track with its deleveraging targets, expecting to meet its
target in the first quarter of 2016.
Loblaw's expectations for 2015 also include the following:
-
competitive intensity expected to remain high, but relatively stable as
industry square footage growth in supermarket-type merchandise
moderates; and
-
continued pressure in its pharmacy business from the ongoing impact of
healthcare reform.
DECLARATION OF QUARTERLY DIVIDENDS
Subsequent to the end of the fourth quarter of 2014, the Company's Board
of Directors declared a quarterly dividend on GWL Common Shares,
Preferred Shares, Series I, Preferred Shares, Series III, Preferred
Shares, Series IV and Preferred Shares, Series V payable as follows:
|
Common Shares
|
$0.42 per share payable April 1, 2015, to
shareholders of record March 15, 2015;
|
|
|
|
|
|
|
Preferred Shares, Series I
|
$0.3625 per share payable March 15, 2015, to
shareholders of record February 28, 2015;
|
|
|
|
|
|
|
Preferred Shares, Series III
|
$0.3250 per share payable April 1, 2015, to
shareholders of record March 15, 2015;
|
|
|
|
|
|
|
Preferred Shares, Series IV
|
$0.3250 per share payable April 1, 2015, to
shareholders of record March 15, 2015; and
|
|
|
|
|
|
|
Preferred Shares, Series V
|
$0.296875 per share payable April 1, 2015, to
shareholders of record March 15, 2015.
|
|
FORWARD-LOOKING STATEMENTS
This News Release contains forward-looking statements about the
Company's objectives, plans, goals, aspirations, strategies, financial
condition, results of operations, cash flows, performance, prospects
and opportunities. Specific forward-looking statements in this News
Release include, but are not limited to, statements with respect to the
Company's anticipated future results, events and plans, synergies and
other benefits associated with the acquisition of Shoppers Drug Mart,
future liquidity and debt reduction targets, and planned capital
investments. These specific forward-looking statements are contained
throughout this News Release including, without limitation, the Outlook
section of this News Release. Forward-looking statements are typically
identified by words such as "expect", "anticipate", "believe",
"foresee", "could", "estimate", "goal", "intend", "plan", "seek",
"strive", "will", "may", "on-track", "maintain", "achieve", "grow", and
"should" and similar expressions, as they relate to the Company and its
management.
Forward-looking statements reflect the Company's current estimates,
beliefs and assumptions, which are based on management's perception of
historical trends, current conditions and expected future developments,
as well as other factors it believes are appropriate in the
circumstances. The Company's expectation of operating and financial
performance in 2015 is based on certain assumptions including
assumptions about sales and volume growth, anticipated cost savings,
operating efficiencies, and continued growth from current initiatives.
The Company's estimates, beliefs and assumptions are inherently subject
to significant business, economic, competitive and other uncertainties
and contingencies regarding future events and as such, are subject to
change. The Company can give no assurance that such estimates, beliefs
and assumptions will prove to be correct.
Numerous risks and uncertainties could cause the Company's actual
results to differ materially from those expressed, implied or projected
in the forward-looking statements, including those described in Section
16, "Enterprise Risks and Risk Management" of the MD&A included in the
Company's 2014 Annual Report and the Company's Annual Information Form
("AIF") for the year ended December 31, 2014. Such risks and
uncertainties include:
-
failure by Loblaw to realize the anticipated strategic benefits or
operational, competitive and cost synergies following the acquisition
of Shoppers Drug Mart;
-
failure by Loblaw to reduce indebtedness associated with the acquisition
of Shoppers Drug Mart to bring leverage ratios to a level consistent
with investment grade ratings;
-
failure to realize benefits from investments in the Company's IT
systems, including the Company's IT systems implementation, or
unanticipated results from these initiatives;
-
failure to realize anticipated results, including revenue growth,
anticipated cost savings or operating efficiencies from the Company's
major initiatives, including those from restructuring;
-
the inability of the Company's IT infrastructure to support the
requirements of the Company's business;
-
changes in Loblaw's estimate of inventory cost as a result of its IT
system upgrade;
-
changes to the regulation of generic prescription drug prices and the
reduction of reimbursements under public drug benefit plans and the
elimination or reduction of professional allowances paid by drug
manufacturers;
-
failure to achieve desired results in labour negotiations, including the
terms of future collective bargaining agreements which could lead to
work stoppages;
-
heightened competition, whether from current competitors or new entrants
to the marketplace;
-
changes in economic conditions including the rate of inflation or
deflation, changes in interest and currency exchange rates and
derivative and commodity prices;
-
changes in the Company's income, capital, commodity, property and other
tax and regulatory liabilities including changes in tax laws,
regulations or future assessments;
-
the inability of the Company to manage inventory to minimize the impact
of obsolete or excess inventory and to control shrink;
-
the risk that the Company would experience a financial loss if its
counterparties fail to meet their obligations in accordance with the
terms and conditions of their contracts with the Company; and
-
the inability of the Company to collect on and fund its credit card
receivables.
This is not an exhaustive list of the factors that may affect the
Company's forward-looking statements. Other risks and uncertainties not
presently known to the Company or that the Company presently believes
are not material could also cause actual results or events to differ
materially from those expressed in its forward-looking statements.
Additional risks and uncertainties are discussed in the Company's
materials filed with the Canadian securities regulatory authorities
from time to time, including without limitation, the section entitled
"Operating and Financial Risks and Risk Management" in the Company's
AIF for the year ended December 31, 2014. Readers are cautioned not to
place undue reliance on these forward-looking statements, which reflect
the Company's expectations only as of the date of this News Release.
Except as required by law, the Company does not undertake to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
NON-GAAP FINANCIAL MEASURES
The Company uses the following non-GAAP financial measures: EBITDA,
adjusted EBITDA and adjusted EBITDA margin, adjusted operating income
and adjusted operating margin, adjusted basic net earnings per common
share from continuing operations, adjusted debt, and free cash flow. In
addition to these items, the Company has now detailed the following
measures used by management in calculating adjusted basic net earnings
per common share from continuing operations: adjusted net interest
expense and other financing charges, adjusted income taxes, adjusted
income tax rate and adjusted net earnings available to common
shareholders of the Company. The Company believes these non-GAAP
financial measures provide useful information to both management and
investors in measuring the financial performance of the Company for the
reasons outlined below.
Management uses these and other non-GAAP financial measures to exclude
the impact of certain expenses and income that must be recognized under
GAAP when analyzing consolidated and segment underlying operating
performance. The excluded items are not necessarily reflective of the
Company's underlying operating performance and make comparisons of
underlying financial performance between periods difficult. From time
to time, the Company may exclude additional items if it believes doing
so would result in a more effective analysis of underlying operating
performance. The exclusion of certain items does not imply that they
are non-recurring.
During 2014, management made the following changes to the calculation of
certain non-GAAP financial measures when analyzing consolidated and
segment underlying operating performance:
-
equity-settled share-based compensation is no longer excluded as an
adjusted item. As a result, prior year non-GAAP financial measures
including these items were restated to conform with the current year's
presentation;
-
net interest expense incurred in connection with the financing related
to the acquisition of Shoppers Drug Mart is no longer excluded as an
adjusted item. These amounts were excluded in periods prior to the
closing of the acquisition of Shoppers Drug Mart; and
-
Choice Properties' general and administrative costs are no longer
excluded in periods where these costs were incurred in the comparative
period. These costs continue to be excluded in periods where they were
not incurred in the comparative period in order to make comparisons of
underlying financial information more useful.
These measures do not have a standardized meaning prescribed by GAAP and
therefore they may not be comparable to similarly titled measures
presented by other publicly traded companies, and they should not be
construed as an alternative to other financial measures determined in
accordance with GAAP.
EBITDA, Adjusted EBITDA and Adjusted Operating Income The Company believes adjusted EBITDA is useful in assessing the
underlying operating performance of the Company's ongoing operations
and in assessing the Company's ability to generate cash flows to fund
its cash requirements, including its capital investments program and
debt reduction objectives. The Company believes adjusted operating
income is also useful in assessing the Company's underlying operating
performance and in making decisions regarding the ongoing operations of
its business.
The following table reconciles EBITDA, adjusted EBITDA and adjusted
operating income to operating income, which is reconciled to GAAP net
earnings from continuing operations attributable to shareholders of the
Company reported for the periods ended as indicated.
|
Quarters Ended
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dec. 31, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
Dec. 31, 2013(i)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(13 weeks)
|
|
|
|
|
|
|
|
|
|
|
|
|
(12 weeks)
|
|
|
(unaudited)
($ millions)
|
|
Weston
Foods
|
|
Loblaw
|
|
Other(ii)
|
|
Consolidated
|
|
|
|
Weston
Foods
|
|
Loblaw
|
|
Other(ii)
|
|
Consolidated
|
|
|
Net earnings attributable to shareholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
of the Company
|
|
|
|
|
|
|
|
|
|
|
$
|
161
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
177
|
|
|
Add impact of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
|
135
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42
|
|
|
|
Income taxes
|
|
|
|
|
|
|
|
|
|
|
|
95
|
|
|
|
|
|
|
|
|
|
|
|
|
|
51
|
|
|
|
Net interest expense and other financing charges
|
|
|
|
|
|
|
|
|
|
|
|
231
|
|
|
|
|
|
|
|
|
|
|
|
|
|
106
|
|
|
Operating income
|
|
$
|
74
|
|
$
|
505
|
|
$
|
43
|
|
$
|
622
|
|
|
|
$
|
40
|
|
$
|
294
|
|
$
|
42
|
|
$
|
376
|
|
|
Depreciation and amortization
|
|
|
17
|
|
|
393
|
|
|
|
|
|
410
|
|
|
|
|
16
|
|
|
196
|
|
|
|
|
|
212
|
|
|
EBITDA
|
|
$
|
91
|
|
$
|
898
|
|
$
|
43
|
|
$
|
1,032
|
|
|
|
$
|
56
|
|
$
|
490
|
|
$
|
42
|
|
$
|
588
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
$
|
74
|
|
$
|
505
|
|
$
|
43
|
|
$
|
622
|
|
|
|
$
|
40
|
|
$
|
294
|
|
$
|
42
|
|
$
|
376
|
|
|
Add (deduct) impact of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recognition of fair value increment on
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
inventory sold
|
|
|
|
|
|
69
|
|
|
|
|
|
69
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of intangible assets acquired
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
with Shoppers Drug Mart
|
|
|
|
|
|
124
|
|
|
|
|
|
124
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shoppers Drug Mart acquisition costs and net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
divestitures loss
|
|
|
|
|
|
14
|
|
|
|
|
|
14
|
|
|
|
|
|
|
|
7
|
|
|
|
|
|
7
|
|
|
|
Restructuring and other charges
|
|
|
2
|
|
|
|
|
|
|
|
|
2
|
|
|
|
|
3
|
|
|
32
|
|
|
|
|
|
35
|
|
|
|
Restructuring of franchise fees
|
|
|
|
|
|
(40)
|
|
|
|
|
|
(40)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed asset and other related impairments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(recoveries)
|
|
|
|
|
|
1
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
(42)
|
|
|
|
|
|
(42)
|
|
|
|
Fair value adjustment of Shoppers Drug Mart's
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
share-based compensation liability
|
|
|
|
|
|
2
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value adjustment of derivatives
|
|
|
(7)
|
|
|
4
|
|
|
|
|
|
(3)
|
|
|
|
|
4
|
|
|
|
|
|
|
|
|
4
|
|
|
|
MEPP withdrawal liability
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5
|
|
|
|
|
|
|
|
|
5
|
|
|
|
Net insurance proceeds
|
|
|
(12)
|
|
|
|
|
|
|
|
|
(12)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation gain
|
|
|
|
|
|
|
|
|
(43)
|
|
|
(43)
|
|
|
|
|
|
|
|
|
|
|
(42)
|
|
|
(42)
|
|
|
Adjusted operating income
|
|
$
|
57
|
|
$
|
679
|
|
|
|
|
$
|
736
|
|
|
|
$
|
52
|
|
$
|
291
|
|
|
|
|
$
|
343
|
|
|
Depreciation and amortization excluding the
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
impact of the above adjustments(iii)
|
|
|
17
|
|
|
269
|
|
|
|
|
|
286
|
|
|
|
|
15
|
|
|
196
|
|
|
|
|
|
211
|
|
|
Adjusted EBITDA
|
|
$
|
74
|
|
$
|
948
|
|
|
|
|
$
|
1,022
|
|
|
|
$
|
67
|
|
$
|
487
|
|
|
|
|
$
|
554
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i)
|
Certain 2013 figures have been amended. See note 2 of the Company's
consolidated financial statements included in the 2014 Annual Report.
|
(ii)
|
Represents the effect of foreign currency translation on a portion of
the United States ("U.S.") dollar denominated cash and short term
investments held by foreign operations.
|
(iii)
|
Depreciation and amortization for the calculation of adjusted EBITDA
excludes $124 million (2013 - nil) of amortization of intangible assets
acquired with Shoppers Drug Mart at Loblaw, and in the fourth quarter
of 2013, $1 million of accelerated depreciation recorded as
restructuring and other charges at Weston Foods.
|
|
|
|
Years Ended
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dec. 31, 2014
|
|
|
|
|
|
|
|
|
|
|
|
|
Dec. 31, 2013(i)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(53 weeks)
|
|
|
|
|
|
|
|
|
|
|
|
|
(52 weeks)
|
|
|
(unaudited)
($ millions)
|
|
Weston
Foods
|
|
Loblaw
|
|
Other(ii)
|
|
Consolidated
|
|
|
|
Weston
Foods
|
|
Loblaw
|
|
Other(ii)
|
|
Consolidated
|
|
|
Net earnings from continuing operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
attributable to shareholders of the Company
|
|
|
|
|
|
|
|
|
|
|
$
|
126
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
614
|
|
|
Add impact of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
232
|
|
|
|
Income taxes
|
|
|
|
|
|
|
|
|
|
|
|
24
|
|
|
|
|
|
|
|
|
|
|
|
|
|
273
|
|
|
|
Net interest expense and other financing charges
|
|
|
|
|
|
|
|
|
|
|
|
815
|
|
|
|
|
|
|
|
|
|
|
|
|
|
497
|
|
|
Operating income
|
|
$
|
231
|
|
$
|
654
|
|
$
|
88
|
|
$
|
973
|
|
|
|
$
|
238
|
|
$
|
1,303
|
|
$
|
75
|
|
$
|
1,616
|
|
|
Depreciation and amortization
|
|
|
70
|
|
|
1,472
|
|
|
|
|
|
1,542
|
|
|
|
|
67
|
|
|
824
|
|
|
|
|
|
891
|
|
|
EBITDA
|
|
$
|
301
|
|
$
|
2,126
|
|
$
|
88
|
|
$
|
2,515
|
|
|
|
$
|
305
|
|
$
|
2,127
|
|
$
|
75
|
|
$
|
2,507
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
$
|
231
|
|
$
|
654
|
|
$
|
88
|
|
$
|
973
|
|
|
|
$
|
238
|
|
$
|
1,303
|
|
$
|
75
|
|
$
|
1,616
|
|
|
Add (deduct) impact of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recognition of fair value increment on
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
inventory sold
|
|
|
|
|
|
798
|
|
|
|
|
|
798
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of intangible assets acquired
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
with Shoppers Drug Mart
|
|
|
|
|
|
417
|
|
|
|
|
|
417
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charge related to inventory measurement and
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
other conversion differences
|
|
|
|
|
|
190
|
|
|
|
|
|
190
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shoppers Drug Mart acquisition costs and net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
divestitures loss
|
|
|
|
|
|
72
|
|
|
|
|
|
72
|
|
|
|
|
|
|
|
16
|
|
|
|
|
|
16
|
|
|
|
Restructuring and other charges
|
|
|
7
|
|
|
46
|
|
|
|
|
|
53
|
|
|
|
|
6
|
|
|
35
|
|
|
|
|
|
41
|
|
|
|
Restructuring of franchise fees
|
|
|
|
|
|
(40)
|
|
|
|
|
|
(40)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed asset and other related impairments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(recoveries)
|
|
|
|
|
|
16
|
|
|
|
|
|
16
|
|
|
|
|
|
|
|
(32)
|
|
|
|
|
|
(32)
|
|
|
|
Choice Properties general and administrative costs
|
|
|
|
|
|
9
|
|
|
|
|
|
9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value adjustment of Shoppers Drug Mart's
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
share-based compensation liability
|
|
|
|
|
|
7
|
|
|
|
|
|
7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Choice Properties start-up costs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3
|
|
|
|
|
|
3
|
|
|
|
Defined benefit plan amendments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(51)
|
|
|
|
|
|
(51)
|
|
|
|
Fair value adjustment of derivatives
|
|
|
(4)
|
|
|
4
|
|
|
|
|
|
|
|
|
|
|
10
|
|
|
|
|
|
|
|
|
10
|
|
|
|
MEPP settlement payment
|
|
|
8
|
|
|
|
|
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MEPP withdrawal liability
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5
|
|
|
|
|
|
|
|
|
5
|
|
|
|
Net insurance proceeds
|
|
|
(1)
|
|
|
|
|
|
|
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation gain
|
|
|
|
|
|
|
|
|
(88)
|
|
|
(88)
|
|
|
|
|
|
|
|
|
|
|
(75)
|
|
|
(75)
|
|
|
Adjusted operating income
|
|
$
|
241
|
|
$
|
2,173
|
|
|
|
|
$
|
2,414
|
|
|
|
$
|
259
|
|
$
|
1,274
|
|
|
|
|
$
|
1,533
|
|
|
Depreciation and amortization excluding the
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
impact of the above adjustments(iii)
|
|
|
70
|
|
|
1,055
|
|
|
|
|
|
1,125
|
|
|
|
|
63
|
|
|
824
|
|
|
|
|
|
887
|
|
|
Adjusted EBITDA
|
|
$
|
311
|
|
$
|
3,228
|
|
|
|
|
$
|
3,539
|
|
|
|
$
|
322
|
|
$
|
2,098
|
|
|
|
|
$
|
2,420
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i)
|
Certain 2013 figures have been amended. See note 2 of the Company's
consolidated financial statements included in the 2014 Annual Report.
|
(ii)
|
Represents the effect of foreign currency translation on a portion of
the U.S. dollar denominated cash and short term investments held by
foreign operations.
|
(iii)
|
Year-to-date depreciation and amortization for the calculation of
adjusted EBITDA at Loblaw excludes $417 million (2013 - nil) of
amortization of intangible assets acquired with Shoppers Drug Mart, and
in 2013, $4 million of accelerated depreciation recorded as
restructuring and other charges at Weston Foods.
|
The year-over-year change in the following items influenced operating
income in the fourth quarter of 2014:
Recognition of the fair value increment on inventory sold In connection with the acquisition of Shoppers Drug Mart, acquired
assets and liabilities were recorded on the Company's consolidated
balance sheet at their fair value. This resulted in a fair value
adjustment to Shoppers Drug Mart inventory on the date of acquisition
representing the difference between inventory cost and its fair value.
In the fourth quarter of 2014, $69 million (2013 - nil) was recognized
in gross profit and operating income.
Amortization of intangible assets acquired with Shoppers Drug Mart The acquisition of Shoppers Drug Mart in the second quarter of 2014
included approximately $6 billion of definite life intangible assets,
which are being amortized over their estimated useful lives. In the
fourth quarter of 2014, $124 million (2013 - nil) of amortization was
recognized in operating income. Loblaw expects to recognize annual
amortization of approximately $550 million associated with the acquired
intangible assets over the next ten years and decreasing thereafter.
Shoppers Drug Mart acquisition costs and net divestitures loss In the fourth quarter of 2014, Loblaw recognized a net loss of $14
million (2013 - nil) related to store divestitures required by the
Competition Bureau as a result of Loblaw's acquisition of Shoppers Drug
Mart. Further adjustments for divestiture gains or losses will be made
when the remaining three Shoppers Drug Mart stores are sold in the
first quarter of 2015. In connection with the acquisition of Shoppers
Drug Mart, in the fourth quarter of 2013 Loblaw recorded $7 million of
acquisition costs.
Restructuring and other charges The Company continuously evaluates strategic and cost reduction
initiatives related to its store infrastructure, manufacturing assets,
distribution networks and administrative infrastructure with the
objective of ensuring a low cost operating structure. Restructuring
activities related to these initiatives are ongoing.
Restructuring of franchise fees In the fourth quarter of 2014, Loblaw restructured its fee
arrangements with franchisees of certain franchise banners. As a result
of this restructuring, Loblaw re-evaluated the recoverable amount of
franchise related financial instruments and recorded a reversal of
previously recorded impairment of $40 million (2013 - nil).
Fixed asset and other related impairments (recoveries) At each balance sheet date, the Company assesses and, when required,
records impairments and reversals of previous impairments related to
the carrying value of its fixed assets, investment properties and
intangible assets. In the fourth quarter of 2014, Loblaw recorded a net
charge of $1 million (2013 - net recoveries of $42 million) related to
fixed assets and other related impairments.
Fair value adjustment of Shoppers Drug Mart's share-based compensation
liability In the second quarter of 2014, in conjunction with Loblaw's acquisition
of Shoppers Drug Mart, Loblaw converted certain Shoppers Drug Mart
cash-settled share-based compensation awards to cash-settled awards
based on Loblaw's common shares. Loblaw is exposed to market price
fluctuations in its common share price as these awards are settled in
cash and the associated liability is recorded at fair value each
reporting date based on the market price of Loblaw's common shares. In
the fourth quarter of 2014, Loblaw recorded a loss of $2 million (2013
- nil). On November 10, 2014, Loblaw amended these awards so they are
settled in shares and accordingly exposure to market price fluctuations
has been eliminated.
Fair value adjustment of derivatives The Company is exposed to commodity price and U.S. dollar exchange
rate fluctuations primarily as a result of purchases of certain raw
materials, fuel and utilities. In accordance with the Company's
commodity risk management policy, the Company enters into commodity and
foreign currency derivatives to reduce the impact of price fluctuations
in forecasted raw material and fuel purchases over a specified period
of time. These derivatives are not acquired for trading or speculative
purposes. Pursuant to the Company's derivative instruments accounting
policy, certain changes in fair value, which include realized and
unrealized gains and losses related to future purchases of raw
materials and fuel, are recorded in operating income. In the fourth
quarter of 2014, Weston Foods recorded income of $7 million (2013 -
charge of $4 million) and Loblaw recorded a charge of $4 million (2013
- nil), related to the fair value adjustment of commodity and foreign
currency derivatives. Despite the impact of accounting for these
commodity and foreign currency derivatives on the Company's reported
results, the derivatives have the economic impact of largely mitigating
the associated risks arising from price and exchange rate fluctuations
in the underlying commodities.
Multi-employer pension plan ("MEPP") withdrawal liability In 2012, Weston Foods withdrew from one of the U.S. MEPPs in which it
participated. The Company recorded $5 million (U.S. $5 million) in the
fourth quarter of 2013 in selling, general and administrative expenses
associated with its withdrawal liability.
Net insurance proceeds On August 31, 2014, a weather event in the U.S. caused significant
damage to Weston Foods inventories stored at a third-party warehouse.
During the fourth quarter of 2014, net proceeds of $12 million (U.S.
$11 million) were received and recorded in selling, general and
administrative expenses. Additional losses or charges associated with
this inventory will be recorded as incurred and any additional proceeds
will be recorded as they are received.
Foreign currency translation gains and losses The Company's consolidated financial statements are expressed in
Canadian dollars. A portion of the Company's (excluding Loblaw's) net
assets are denominated in U.S. dollars and as a result, the Company is
exposed to foreign currency translation gains and losses. The impact of
foreign currency translation on a portion of the U.S. dollar
denominated net assets, primarily cash and short term investments held
by foreign operations, is recorded in operating income. In the fourth
quarter of 2014, a foreign currency translation gain of $43 million
(2013 - $42 million) was recorded in operating income as a result of
the appreciation of the U.S. dollar relative to the Canadian dollar.
Adjusted Net Interest Expense and Other Financing Charges The Company believes adjusted net interest expense and other financing
charges is useful in assessing the ongoing net financing costs of the
Company.
The following table reconciles adjusted net interest expense and other
financing charges to GAAP net interest expense and other financing
charges reported for the periods ended as indicated.
|
|
Quarters Ended
|
|
|
Years Ended
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(unaudited)
|
|
Dec. 31, 2014
|
|
|
Dec. 31, 2013
|
|
|
Dec. 31, 2014
|
|
|
Dec. 31, 2013
|
|
($ millions)
|
|
(13 weeks)
|
|
|
(12 weeks)
|
|
|
(53 weeks)
|
|
|
(52 weeks)
|
|
Net interest expense and other financing charges
|
|
$
|
231
|
|
|
$
|
106
|
|
|
$
|
815
|
|
|
$
|
497
|
|
Less:
|
Fair value adjustment of the forward sale
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
agreement for 9.6 million Loblaw
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
common shares
|
|
|
59
|
|
|
|
(34)
|
|
|
|
199
|
|
|
|
(1)
|
|
|
Accelerated amortization of deferred
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
financing costs
|
|
|
5
|
|
|
|
|
|
|
|
23
|
|
|
|
|
|
|
Shoppers Drug Mart net financing charges
|
|
|
|
|
|
|
14
|
|
|
|
15
|
|
|
|
15
|
|
|
Fair value adjustment of Trust Unit liability
|
|
|
14
|
|
|
|
23
|
|
|
|
12
|
|
|
|
18
|
|
|
Choice Properties IPO transaction costs
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
44
|
|
|
Early debt settlement costs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18
|
|
Adjusted net interest expense and other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
financing charges
|
|
$
|
153
|
|
|
$
|
102
|
|
|
$
|
566
|
|
|
$
|
403
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In addition to certain items described in the "EBITDA, Adjusted EBITDA
and Adjusted Operating Income" section above, the following items
impacted net interest expense and other financing charges in the fourth
quarters of 2014 and 2013:
Fair value adjustment of the forward sale agreement for 9.6 million
Loblaw common shares The fair value adjustment of the forward sale agreement for 9.6 million
Loblaw common shares is non-cash and is included in net interest
expense and other financing charges. The adjustment is determined by
changes in the value of the underlying Loblaw common shares. In the
fourth quarter of 2014, a charge of $59 million (2013 - income of
$34 million) was recorded in net interest expense and other financing
charges as a result of the changes in the market price of Loblaw common
shares. An increase (decrease) in the market price of Loblaw common
shares results in a charge (income) to net interest expense and other
financing charges.
Accelerated amortization of deferred financing costs In the fourth quarter of 2014, Loblaw recorded a charge of $5 million
(2013 - nil) related to the accelerated amortization of deferred
financing costs due to the repayment of $321 million of Loblaw's term
loan facility.
Shoppers Drug Mart net financing charges In addition to the acquisition costs described in the EBITDA, Adjusted
EBITDA and Adjusted Operating Income section above, during the fourth
quarter of 2013, net charges of $14 million were incurred in connection
with financing related to the acquisition of Shoppers Drug Mart.
Fair value adjustment of Trust Unit liability The Company is exposed to market price fluctuations as a result of the
Choice Properties Trust Units held by unitholders other than the
Company. These Trust Units are presented as a liability on the
Company's consolidated balance sheets as they are redeemable for cash
at the option of the holder, subject to certain restrictions. This
liability is recorded at fair value at each reporting period based on
the market price of Trust Units at the end of each period. In the
fourth quarter of 2014, the Company recorded a loss of $14 million
(2013 - $23 million) in net interest expense and other financing
charges related to the fair value adjustment of the Trust Unit
liability as a result of an increase in the market price of Trust
Units. An increase (decrease) in the market price of Trust Units
results in a charge (income) to net interest expense and other
financing charges.
Choice Properties initial public offering ("IPO") transaction costs In connection with the IPO of Choice Properties in the third quarter of
2013, transaction costs of $1 million were incurred in the fourth
quarter of 2013.
Adjusted Income Taxes and Adjusted Income Tax Rate The Company believes the adjusted income tax rate applicable to adjusted
earnings before taxes is useful in assessing the underlying operating
performance of its business.
The following table reconciles the effective income tax rate applicable
to adjusted earnings before taxes to the GAAP effective income tax rate
applicable to earnings before taxes as reported for the periods ended
as indicated.
|
|
Quarters Ended
|
|
|
Years Ended
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(unaudited)
|
|
Dec. 31, 2014
|
|
|
Dec. 31, 2013(i)
|
|
|
Dec. 31, 2014
|
|
|
Dec. 31, 2013(i)
|
|
($ millions except where otherwise indicated)
|
|
(13 weeks)
|
|
|
(12 weeks)
|
|
|
(53 weeks)
|
|
|
(52 weeks)
|
|
Adjusted operating income(ii)
|
|
$
|
736
|
|
|
$
|
343
|
|
|
$
|
2,414
|
|
|
$
|
1,533
|
|
Adjusted net interest expense and other financing charges(ii)
|
|
|
153
|
|
|
|
102
|
|
|
|
566
|
|
|
|
403
|
|
Adjusted earnings before taxes
|
|
$
|
583
|
|
|
$
|
241
|
|
|
$
|
1,848
|
|
|
$
|
1,130
|
|
Income taxes
|
|
$
|
95
|
|
|
$
|
51
|
|
|
$
|
24
|
|
|
$
|
273
|
|
Less: Tax impact of items excluded from adjusted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
earnings before taxes(iii)
|
|
|
(60)
|
|
|
|
6
|
|
|
|
(457)
|
|
|
|
(12)
|
|
Adjusted income taxes
|
|
$
|
155
|
|
|
$
|
45
|
|
|
$
|
481
|
|
|
$
|
285
|
|
Effective income tax rate applicable to earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
before taxes
|
|
|
24.3%
|
|
|
|
18.9%
|
|
|
|
15.2%
|
|
|
|
24.4%
|
|
Adjusted income tax rate applicable to adjusted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
earnings before taxes
|
|
|
26.6%
|
|
|
|
18.7%
|
|
|
|
26.0%
|
|
|
|
25.2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i)
|
Certain 2013 figures have been amended. See note 2 of the Company's
consolidated financial statements included in the 2014 Annual Report.
|
(ii)
|
See reconciliations of adjusted operating income and adjusted net
interest expense and other financing charges above.
|
(iii)
|
See the EBITDA, adjusted EBITDA and adjusted operating income table and
the adjusted net interest expense and other financing charges table
above for a complete list of items excluded from adjusted earnings
before taxes.
|
Adjusted Basic Net Earnings per Common Share from Continuing Operations
and Adjusted Net Earnings from Continuing Operations The Company believes adjusted basic net earnings per common share from
continuing operations and adjusted net earnings from continuing
operations are useful in assessing the Company's underlying operating
performance and in making decisions regarding the ongoing operations of
its business.
The following table reconciles adjusted basic net earnings per common
share from continuing operations and adjusted net earnings from
continuing operations to GAAP basic net earnings per common share from
continuing operations reported for the periods ended as indicated.
|
|
Quarters Ended
|
|
|
|
Years Ended
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(unaudited)
|
|
Dec. 31, 2014
|
|
|
|
Dec. 31, 2013(i)
|
|
|
|
Dec. 31, 2014
|
|
|
|
Dec. 31, 2013(i)
|
|
|
($)
|
|
(13 weeks)
|
|
|
|
(12 weeks)
|
|
|
|
(53 weeks)
|
|
|
|
(52 weeks)
|
|
|
Basic net earnings per common share from
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
continuing operations
|
|
$
|
1.18
|
|
|
|
$
|
1.31
|
|
|
|
$
|
0.64
|
|
|
|
$
|
4.47
|
|
|
Add (deduct) impact of the following(ii):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value adjustment of the forward sale
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
agreement for 9.6 million Loblaw common shares
|
|
|
0.35
|
|
|
|
|
(0.21)
|
|
|
|
|
1.17
|
|
|
|
|
(0.01)
|
|
|
|
Recognition of fair value increment on inventory sold
|
|
|
0.17
|
|
|
|
|
|
|
|
|
|
2.08
|
|
|
|
|
|
|
|
|
Amortization of intangible assets acquired
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
with Shoppers Drug Mart
|
|
|
0.33
|
|
|
|
|
|
|
|
|
|
1.09
|
|
|
|
|
|
|
|
|
Charge related to inventory measurement and other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
conversion differences
|
|
|
|
|
|
|
|
|
|
|
|
|
0.49
|
|
|
|
|
|
|
|
|
Shoppers Drug Mart acquisition costs and
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
net financing charges
|
|
|
0.04
|
|
|
|
|
0.08
|
|
|
|
|
0.29
|
|
|
|
|
0.13
|
|
|
|
Restructuring and other charges
|
|
|
0.01
|
|
|
|
|
0.14
|
|
|
|
|
0.17
|
|
|
|
|
0.17
|
|
|
|
Restructuring of franchise fees
|
|
|
(0.11)
|
|
|
|
|
|
|
|
|
|
(0.11)
|
|
|
|
|
|
|
|
|
Fixed asset and other related impairments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(recoveries)
|
|
|
|
|
|
|
|
(0.14)
|
|
|
|
|
0.05
|
|
|
|
|
(0.11)
|
|
|
|
Choice Properties general and administrative costs
|
|
|
|
|
|
|
|
|
|
|
|
|
0.03
|
|
|
|
|
|
|
|
|
Fair value adjustment of Shoppers Drug Mart's
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
share-based compensation liability
|
|
|
|
|
|
|
|
|
|
|
|
|
0.02
|
|
|
|
|
|
|
|
|
Choice Properties start-up and IPO transaction costs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.17
|
|
|
|
Defined benefit plan amendments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(0.18)
|
|
|
|
Fair value adjustment of derivatives
|
|
|
(0.03)
|
|
|
|
|
0.03
|
|
|
|
|
(0.01)
|
|
|
|
|
0.06
|
|
|
|
MEPP settlement payment
|
|
|
|
|
|
|
|
|
|
|
|
|
0.04
|
|
|
|
|
|
|
|
|
MEPP withdrawal liability
|
|
|
|
|
|
|
|
0.02
|
|
|
|
|
|
|
|
|
|
0.02
|
|
|
|
Net insurance proceeds
|
|
|
(0.06)
|
|
|
|
|
|
|
|
|
|
(0.01)
|
|
|
|
|
|
|
|
|
Fair value adjustment of Trust Unit liability
|
|
|
0.03
|
|
|
|
|
0.08
|
|
|
|
|
0.04
|
|
|
|
|
0.06
|
|
|
|
Accelerated amortization of deferred financing costs
|
|
|
0.01
|
|
|
|
|
|
|
|
|
|
0.06
|
|
|
|
|
|
|
|
|
Early debt settlement costs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.06
|
|
|
|
Foreign currency translation gain
|
|
|
(0.34)
|
|
|
|
|
(0.33)
|
|
|
|
|
(0.69)
|
|
|
|
|
(0.59)
|
|
|
Adjusted basic net earnings per common share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
from continuing operations
|
|
$
|
1.58
|
|
|
|
$
|
0.98
|
|
|
|
$
|
5.35
|
|
|
|
$
|
4.25
|
|
|
Weighted average common shares outstanding (millions)
|
|
|
127.7
|
|
|
|
|
127.7
|
|
|
|
|
127.8
|
|
|
|
|
127.6
|
|
|
Adjusted net earnings from continuing operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
attributable to shareholders of the Company
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(millions of Canadian dollars)
|
|
$
|
212
|
|
|
|
$
|
135
|
|
|
|
$
|
728
|
|
|
|
$
|
586
|
|
|
Prescribed dividends on preferred shares in share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
capital (millions of Canadian dollars)
|
|
|
10
|
|
|
|
|
10
|
|
|
|
|
44
|
|
|
|
|
44
|
|
|
Adjusted net earnings from continuing operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
available to common shareholders of the Company
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(millions of Canadian dollars)
|
|
$
|
202
|
|
|
|
$
|
125
|
|
|
|
$
|
684
|
|
|
|
$
|
542
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i)
|
Certain 2013 figures have been amended. See note 2 of the Company's
consolidated financial statements included in the 2014 Annual Report.
|
(ii)
|
Net of income taxes and non-controlling interests, as applicable.
|
Adjusted Debt The Company believes adjusted debt is useful in assessing the amount of
financial leverage employed. The Company changed its definition of
adjusted debt in the second quarter of 2014 to include capital
securities to better align with management's definition for
deleveraging purposes. In the table below, the Company has presented
adjusted debt as at March 28, 2014, the date of acquisition of Shoppers
Drug Mart, as this is the baseline for the Company's debt reduction
targets.
The following table reconciles adjusted debt to GAAP measures reported
as at the periods ended as indicated.
|
|
As at
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
($ millions)
|
|
Dec. 31, 2014
|
|
|
|
Mar. 28, 2014
|
|
|
|
Dec. 31, 2013
|
|
|
Bank indebtedness
|
|
$
|
162
|
|
|
|
$
|
295
|
|
|
|
|
|
|
|
Short term debt
|
|
|
1,101
|
|
|
|
|
1,070
|
|
|
|
$
|
1,060
|
|
|
Long term debt due within one year
|
|
|
420
|
|
|
|
|
902
|
|
|
|
|
1,208
|
|
|
Long term debt
|
|
|
12,306
|
|
|
|
|
12,327
|
|
|
|
|
7,736
|
|
|
Trust Unit liability
|
|
|
494
|
|
|
|
|
487
|
|
|
|
|
478
|
|
|
Capital securities
|
|
|
225
|
|
|
|
|
224
|
|
|
|
|
224
|
|
|
Certain other liabilities
|
|
|
28
|
|
|
|
|
39
|
|
|
|
|
39
|
|
|
Fair value of financial derivatives related to the above debt
|
|
|
(367)
|
|
|
|
|
(484)
|
|
|
|
|
(524)
|
|
|
Total debt
|
|
$
|
14,369
|
|
|
|
$
|
14,860
|
|
|
|
$
|
10,221
|
|
|
Less:
|
Independent securitization trusts in short term debt
|
|
|
605
|
|
|
|
|
605
|
|
|
|
|
605
|
|
|
|
Independent securitization trusts in long term debt
|
|
|
750
|
|
|
|
|
750
|
|
|
|
|
750
|
|
|
|
Trust Unit liability
|
|
|
494
|
|
|
|
|
487
|
|
|
|
|
478
|
|
|
|
Independent funding trusts
|
|
|
498
|
|
|
|
|
469
|
|
|
|
|
475
|
|
|
|
Guaranteed Investment Certificates
|
|
|
634
|
|
|
|
|
443
|
|
|
|
|
430
|
|
|
Adjusted debt
|
|
|
$
|
11,388
|
|
|
|
$
|
12,106
|
|
|
|
$
|
7,483
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Cash Flow The Company believes free cash flow is useful in assessing the Company's
cash available for additional financing and investing activities. The
Company changed its definition of free cash flow in the fourth quarter
of 2014 to better align with management's definition.
The following table reconciles free cash flow to GAAP measures reported
for the periods ended as indicated.
|
|
Quarters Ended
|
|
|
Years Ended
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(unaudited)
|
|
Dec. 31, 2014
|
|
|
|
Dec. 31, 2013
|
|
|
|
Dec. 31, 2014
|
|
|
|
Dec. 31, 2013
|
|
($ millions)
|
|
(13 weeks)
|
|
|
|
(12 weeks)
|
|
|
|
(53 weeks)
|
|
|
|
(52 weeks)
|
|
Cash flows from operating activities of
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
continuing operations
|
|
$
|
1,090
|
|
|
|
$
|
813
|
|
|
|
$
|
2,851
|
|
|
|
$
|
1,738
|
|
Less:
|
Interest paid
|
|
|
139
|
|
|
|
|
117
|
|
|
|
|
604
|
|
|
|
|
466
|
|
|
Fixed asset purchases
|
|
|
405
|
|
|
|
|
341
|
|
|
|
|
1,124
|
|
|
|
|
976
|
|
|
Intangible asset additions
|
|
|
42
|
|
|
|
|
|
|
|
|
|
90
|
|
|
|
|
12
|
|
Free cash flow
|
|
|
$
|
504
|
|
|
|
$
|
355
|
|
|
|
$
|
1,033
|
|
|
|
$
|
284
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SELECTED FINANCIAL INFORMATION
The following includes selected quarterly financial information which is
prepared by management in accordance with International Financial
Reporting Standards ("IFRS") and is based on the Company's audited
annual consolidated financial statements for the year ended
December 31, 2014. This financial information does not contain all
disclosures required by IFRS, and accordingly, this financial
information should be read in conjunction with the Company's audited
annual consolidated financial statements and MD&A for the year ended
December 31, 2014 which is contained in the Company's 2014 Annual
Report available in the Investor Centre section of the Company's
website at www.weston.ca.
Consolidated Statements of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the periods ended
|
|
Dec. 31, 2014
|
|
|
|
Dec. 31, 2013(3)
|
|
|
|
Dec. 31, 2014
|
|
|
|
Dec. 31, 2013(3)
|
|
(millions of Canadian dollars except where otherwise indicated)
|
|
(13 weeks)
|
|
|
|
(12 weeks)
|
|
|
|
(53 weeks)
|
|
|
|
(52 weeks)
|
|
Revenue
|
|
$
|
11,734
|
|
|
|
$
|
7,919
|
|
|
|
$
|
43,918
|
|
|
|
$
|
33,582
|
|
Operating Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of inventories sold
|
|
|
8,423
|
|
|
|
|
5,959
|
|
|
|
|
32,727
|
|
|
|
|
25,291
|
|
|
Selling, general and administrative expenses
|
|
|
2,689
|
|
|
|
|
1,584
|
|
|
|
|
10,218
|
|
|
|
|
6,675
|
|
|
|
|
11,112
|
|
|
|
|
7,543
|
|
|
|
|
42,945
|
|
|
|
|
31,966
|
|
Operating Income
|
|
|
622
|
|
|
|
|
376
|
|
|
|
|
973
|
|
|
|
|
1,616
|
|
Net Interest Expense and Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing Charges
|
|
|
231
|
|
|
|
|
106
|
|
|
|
|
815
|
|
|
|
|
497
|
|
Earnings Before Income Taxes
|
|
|
391
|
|
|
|
|
270
|
|
|
|
|
158
|
|
|
|
|
1,119
|
|
Income Taxes
|
|
|
95
|
|
|
|
|
51
|
|
|
|
|
24
|
|
|
|
|
273
|
|
Net Earnings from Continuing Operations
|
|
|
296
|
|
|
|
|
219
|
|
|
|
|
134
|
|
|
|
|
846
|
|
Attributable to:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders of the Company
|
|
|
161
|
|
|
|
|
177
|
|
|
|
|
126
|
|
|
|
|
614
|
|
|
Non-Controlling Interests
|
|
|
135
|
|
|
|
|
42
|
|
|
|
|
8
|
|
|
|
|
232
|
|
Net Earnings from Continuing Operations
|
|
|
296
|
|
|
|
|
219
|
|
|
|
|
134
|
|
|
|
|
846
|
|
Discontinued Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
58
|
|
Net Earnings
|
|
$
|
296
|
|
|
|
$
|
219
|
|
|
|
$
|
134
|
|
|
|
$
|
904
|
|
Net Earnings per Common Share ($) - Basic
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing Operations
|
|
$
|
1.18
|
|
|
|
$
|
1.31
|
|
|
|
$
|
0.64
|
|
|
|
$
|
4.47
|
|
|
Discontinued Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
0.46
|
|
|
Net Earnings
|
|
$
|
1.18
|
|
|
|
$
|
1.31
|
|
|
|
$
|
0.64
|
|
|
|
$
|
4.93
|
|
Net Earnings per Common Share ($) - Diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing Operations
|
|
$
|
1.17
|
|
|
|
$
|
1.30
|
|
|
|
$
|
0.64
|
|
|
|
$
|
4.43
|
|
|
Discontinued Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
0.46
|
|
|
Net Earnings
|
|
$
|
1.17
|
|
|
|
$
|
1.30
|
|
|
|
$
|
0.64
|
|
|
|
$
|
4.89
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Balance Sheets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As at December 31
|
|
|
|
|
|
|
|
|
|
|
(millions of Canadian dollars)
|
|
2014
|
|
|
|
2013(3)
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
1,333
|
|
|
|
$
|
2,869
|
|
|
|
Short term investments
|
|
|
1,072
|
|
|
|
|
1,490
|
|
|
|
Accounts receivable
|
|
|
1,318
|
|
|
|
|
697
|
|
|
|
Credit card receivables
|
|
|
2,630
|
|
|
|
|
2,538
|
|
|
|
Inventories
|
|
|
4,463
|
|
|
|
|
2,244
|
|
|
|
Income taxes recoverable
|
|
|
30
|
|
|
|
|
|
|
|
|
Prepaid expenses and other assets
|
|
|
223
|
|
|
|
|
84
|
|
|
|
Assets held for sale
|
|
|
23
|
|
|
|
|
22
|
|
|
Total Current Assets
|
|
|
11,092
|
|
|
|
|
9,944
|
|
|
Fixed Assets
|
|
|
11,436
|
|
|
|
|
9,655
|
|
|
Investment Properties
|
|
|
185
|
|
|
|
|
99
|
|
|
Intangible Assets
|
|
|
9,288
|
|
|
|
|
215
|
|
|
Goodwill
|
|
|
3,681
|
|
|
|
|
1,365
|
|
|
Deferred Income Taxes
|
|
|
215
|
|
|
|
|
307
|
|
|
Security Deposits
|
|
|
92
|
|
|
|
|
1,791
|
|
|
Franchise Loans Receivable
|
|
|
399
|
|
|
|
|
375
|
|
|
Other Assets
|
|
|
683
|
|
|
|
|
853
|
|
|
Total Assets
|
|
$
|
37,071
|
|
|
|
$
|
24,604
|
|
|
LIABILITIES
|
|
|
|
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
Bank indebtedness
|
|
$
|
162
|
|
|
|
|
|
|
|
|
Trade payables and other liabilities
|
|
|
4,832
|
|
|
|
$
|
3,989
|
|
|
|
Provisions
|
|
|
130
|
|
|
|
|
120
|
|
|
|
Income taxes payable
|
|
|
|
|
|
|
|
2
|
|
|
|
Short term debt
|
|
|
1,101
|
|
|
|
|
1,060
|
|
|
|
Long term debt due within one year
|
|
|
420
|
|
|
|
|
1,208
|
|
|
|
Associate interest
|
|
|
193
|
|
|
|
|
|
|
|
|
Capital securities
|
|
|
225
|
|
|
|
|
|
|
|
Total Current Liabilities
|
|
|
7,063
|
|
|
|
|
6,379
|
|
|
Provisions
|
|
|
103
|
|
|
|
|
81
|
|
|
Long Term Debt
|
|
|
12,306
|
|
|
|
|
7,736
|
|
|
Trust Unit Liability
|
|
|
494
|
|
|
|
|
478
|
|
|
Deferred Income Taxes
|
|
|
2,007
|
|
|
|
|
187
|
|
|
Other Liabilities
|
|
|
849
|
|
|
|
|
618
|
|
|
Capital Securities
|
|
|
|
|
|
|
|
224
|
|
|
Total Liabilities
|
|
|
22,822
|
|
|
|
|
15,703
|
|
|
EQUITY
|
|
|
|
|
|
|
|
|
|
|
Share Capital
|
|
|
997
|
|
|
|
|
972
|
|
|
Contributed Surplus
|
|
|
80
|
|
|
|
|
65
|
|
|
Retained Earnings
|
|
|
6,125
|
|
|
|
|
5,260
|
|
|
Accumulated Other Comprehensive Income
|
|
|
87
|
|
|
|
|
16
|
|
|
Total Equity Attributable to Shareholders of the Company
|
|
|
7,289
|
|
|
|
|
6,313
|
|
|
Non-Controlling Interests
|
|
|
6,960
|
|
|
|
|
2,588
|
|
|
Total Equity
|
|
|
14,249
|
|
|
|
|
8,901
|
|
|
Total Liabilities and Equity
|
|
$
|
37,071
|
|
|
|
$
|
24,604
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Statements of Cash Flows
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the periods ended
|
|
Dec. 31, 2014
|
|
|
Dec. 31, 2013(3)
|
|
|
Dec. 31, 2014
|
|
|
Dec. 31, 2013(3)
|
|
|
(millions of Canadian dollars)
|
|
(13 weeks)
|
|
|
(12 weeks)
|
|
|
(53 weeks)
|
|
|
(52 weeks)
|
|
|
Operating Activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net earnings from continuing operations
|
|
$
|
296
|
|
|
$
|
219
|
|
|
$
|
134
|
|
|
$
|
846
|
|
|
|
Income taxes
|
|
|
95
|
|
|
|
51
|
|
|
|
24
|
|
|
|
273
|
|
|
|
Net interest expense and other financing charges
|
|
|
231
|
|
|
|
106
|
|
|
|
815
|
|
|
|
497
|
|
|
|
Depreciation and amortization
|
|
|
410
|
|
|
|
212
|
|
|
|
1,542
|
|
|
|
891
|
|
|
|
Recognition of fair value increment on inventory sold
|
|
|
69
|
|
|
|
|
|
|
|
798
|
|
|
|
|
|
|
|
Charge related to inventory measurement and
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
other conversion differences
|
|
|
|
|
|
|
|
|
|
|
190
|
|
|
|
|
|
|
|
Foreign currency translation gain
|
|
|
(43)
|
|
|
|
(42)
|
|
|
|
(88)
|
|
|
|
(75)
|
|
|
|
Gain on defined benefit plan amendments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(51)
|
|
|
|
Settlement of derivatives
|
|
|
|
|
|
|
76
|
|
|
|
|
|
|
|
59
|
|
|
|
Change in credit card receivables
|
|
|
(81)
|
|
|
|
(108)
|
|
|
|
(92)
|
|
|
|
(233)
|
|
|
|
Change in non-cash working capital
|
|
|
172
|
|
|
|
398
|
|
|
|
(319)
|
|
|
|
(245)
|
|
|
|
Income taxes paid
|
|
|
(74)
|
|
|
|
(75)
|
|
|
|
(317)
|
|
|
|
(271)
|
|
|
|
Interest received
|
|
|
4
|
|
|
|
7
|
|
|
|
35
|
|
|
|
59
|
|
|
|
Other
|
|
|
11
|
|
|
|
(31)
|
|
|
|
129
|
|
|
|
(12)
|
|
|
Cash Flows from Operating Activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
of Continuing Operations
|
|
|
1,090
|
|
|
|
813
|
|
|
|
2,851
|
|
|
|
1,738
|
|
|
Investing Activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fixed asset purchases
|
|
|
(405)
|
|
|
|
(341)
|
|
|
|
(1,124)
|
|
|
|
(976)
|
|
|
|
Change in short term investments
|
|
|
(12)
|
|
|
|
765
|
|
|
|
502
|
|
|
|
730
|
|
|
|
Acquisition of Shoppers Drug Mart, net of cash acquired
|
|
|
|
|
|
|
|
|
|
|
(6,619)
|
|
|
|
|
|
|
|
Change in franchise investments and other receivables
|
|
|
(4)
|
|
|
|
(22)
|
|
|
|
(25)
|
|
|
|
5
|
|
|
|
Change in security deposits
|
|
|
1
|
|
|
|
201
|
|
|
|
1,704
|
|
|
|
(1,435)
|
|
|
|
Intangible asset additions
|
|
|
(42)
|
|
|
|
|
|
|
|
(90)
|
|
|
|
(12)
|
|
|
|
Investment in joint venture
|
|
|
(6)
|
|
|
|
|
|
|
|
(6)
|
|
|
|
|
|
|
|
Other
|
|
|
18
|
|
|
|
2
|
|
|
|
74
|
|
|
|
13
|
|
|
Cash Flows (used in) from Investing Activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
of Continuing Operations
|
|
|
(450)
|
|
|
|
605
|
|
|
|
(5,584)
|
|
|
|
(1,675)
|
|
|
Financing Activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in bank indebtedness
|
|
|
(161)
|
|
|
|
|
|
|
|
(133)
|
|
|
|
|
|
|
|
Change in Associate interest
|
|
|
16
|
|
|
|
|
|
|
|
19
|
|
|
|
|
|
|
|
Change in short term debt
|
|
|
11
|
|
|
|
(289)
|
|
|
|
41
|
|
|
|
(259)
|
|
|
|
Long term debt
|
- Issued, net of financing charges
|
|
|
126
|
|
|
|
473
|
|
|
|
6,036
|
|
|
|
2,749
|
|
|
|
|
- Retired
|
|
|
(341)
|
|
|
|
(469)
|
|
|
|
(3,536)
|
|
|
|
(871)
|
|
|
|
Trust Units
|
- Issued, net of financing charges
|
|
|
1
|
|
|
|
(1)
|
|
|
|
1
|
|
|
|
416
|
|
|
|
Share capital
|
- Issued
|
|
|
2
|
|
|
|
|
|
|
|
21
|
|
|
|
17
|
|
|
|
|
- Purchased and held in trust
|
|
|
|
|
|
|
|
|
|
|
(11)
|
|
|
|
(15)
|
|
|
|
|
- Retired
|
|
|
(16)
|
|
|
|
|
|
|
|
(29)
|
|
|
|
(42)
|
|
|
|
Loblaw share capital
|
- Issued
|
|
|
19
|
|
|
|
8
|
|
|
|
129
|
|
|
|
75
|
|
|
|
|
- Purchased and held in trust
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(46)
|
|
|
|
|
- Retired
|
|
|
(29)
|
|
|
|
|
|
|
|
(178)
|
|
|
|
(73)
|
|
|
|
Interest paid
|
|
|
(139)
|
|
|
|
(117)
|
|
|
|
(604)
|
|
|
|
(466)
|
|
|
|
Dividends
|
- To common shareholders
|
|
|
(53)
|
|
|
|
|
|
|
|
(267)
|
|
|
|
(203)
|
|
|
|
|
- To preferred shareholders
|
|
|
(11)
|
|
|
|
(3)
|
|
|
|
(52)
|
|
|
|
(44)
|
|
|
|
|
- To minority shareholders
|
|
|
(55)
|
|
|
|
|
|
|
|
(273)
|
|
|
|
(96)
|
|
|
|
Contribution from non-controlling interests
|
|
|
8
|
|
|
|
|
|
|
|
8
|
|
|
|
|
|
|
Cash Flows (used in) from Financing Activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
of Continuing Operations
|
|
|
(622)
|
|
|
|
(398)
|
|
|
|
1,172
|
|
|
|
1,142
|
|
|
Effect of foreign currency exchange rate changes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
on cash and cash equivalents
|
|
|
11
|
|
|
|
12
|
|
|
|
25
|
|
|
|
27
|
|
|
Cash Flows from (used in) Continuing Operations
|
|
|
29
|
|
|
|
1,032
|
|
|
|
(1,536)
|
|
|
|
1,232
|
|
|
Cash Flows from Discontinued Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
48
|
|
|
Change in Cash and Cash Equivalents
|
|
|
29
|
|
|
|
1,032
|
|
|
|
(1,536)
|
|
|
|
1,280
|
|
|
Cash and Cash Equivalents, Beginning of Period
|
|
|
1,304
|
|
|
|
1,837
|
|
|
|
2,869
|
|
|
|
1,589
|
|
|
Cash and Cash Equivalents, End of Period
|
|
$
|
1,333
|
|
|
$
|
2,869
|
|
|
$
|
1,333
|
|
|
$
|
2,869
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and Diluted Net Earnings per Common Share from Continuing
Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the periods ended
|
Dec. 31, 2014
|
|
|
Dec. 31, 2013(i)
|
|
|
Dec. 31, 2014
|
|
|
Dec. 31, 2013(i)
|
|
|
(millions of Canadian dollars except where otherwise indicated)
|
(13 weeks)
|
|
|
(12 weeks)
|
|
|
(53 weeks)
|
|
|
(52 weeks)
|
|
|
Net earnings from continuing operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
attributable to shareholders of the Company
|
$
|
161
|
|
|
$
|
177
|
|
|
$
|
126
|
|
|
$
|
614
|
|
|
Prescribed dividends on preferred shares
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
in share capital
|
|
(10)
|
|
|
|
(10)
|
|
|
|
(44)
|
|
|
|
(44)
|
|
|
Net earnings from continuing operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
available to common shareholders
|
$
|
151
|
|
|
$
|
167
|
|
|
$
|
82
|
|
|
$
|
570
|
|
|
Reduction in net earnings due to dilution
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
at Loblaw
|
|
(1)
|
|
|
|
(1)
|
|
|
|
|
|
|
|
(4)
|
|
|
Net earnings from continuing operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
available to common shareholders for
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
diluted earnings per share
|
$
|
150
|
|
|
$
|
166
|
|
|
$
|
82
|
|
|
$
|
566
|
|
|
Weighted average common shares
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
outstanding (in millions)
|
|
127.7
|
|
|
|
127.7
|
|
|
|
127.8
|
|
|
|
127.6
|
|
|
Dilutive effect of share-based
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
compensation(ii) (in millions)
|
|
0.5
|
|
|
|
0.3
|
|
|
|
0.4
|
|
|
|
0.2
|
|
|
Diluted weighted average common shares
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
outstanding (in millions)
|
|
128.2
|
|
|
|
128.0
|
|
|
|
128.2
|
|
|
|
127.8
|
|
|
Basic net earnings per common share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
from continuing operations ($)
|
$
|
1.18
|
|
|
$
|
1.31
|
|
|
$
|
0.64
|
|
|
$
|
4.47
|
|
|
Diluted net earnings per common share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
from continuing operations ($)
|
$
|
1.17
|
|
|
$
|
1.30
|
|
|
$
|
0.64
|
|
|
$
|
4.43
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i)
|
Certain 2013 figures have been amended. See note 2 of the Company's
consolidated financial statements included in the 2014 Annual Report.
|
(ii)
|
In the fourth quarter of 2014 and year-to-date, 79,962 (2013 - 513,585)
and 501,963 (2013 - 516,557) potentially dilutive instruments,
respectively, were excluded from the computation of diluted net
earnings per common share from continuing operations as they
were anti-dilutive.
|
Segment Information
The Company has two reportable operating segments: Weston Foods and
Loblaw. The accounting policies of the reportable operating segments
are the same as those described in the Company's 2014 Annual Report.
The Company measures each reportable operating segment's performance
based on adjusted EBITDA(ii) and adjusted operating income(ii). Neither reportable operating segment is reliant on any single external
customer.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the periods ended
|
Dec. 31, 2014
|
|
|
Dec. 31, 2013(i)
|
|
|
Dec. 31, 2014
|
|
|
Dec. 31, 2013(i)
|
|
|
(millions of Canadian dollars)
|
(13 weeks)
|
|
|
(12 weeks)
|
|
|
(53 weeks)
|
|
|
(52 weeks)
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weston Foods
|
$
|
469
|
|
|
$
|
413
|
|
|
$
|
1,923
|
|
|
$
|
1,812
|
|
|
|
Loblaw
|
|
11,413
|
|
|
|
7,640
|
|
|
|
42,611
|
|
|
|
32,371
|
|
|
|
Intersegment
|
|
(148)
|
|
|
|
(134)
|
|
|
|
(616)
|
|
|
|
(601)
|
|
|
Consolidated
|
|
$
|
11,734
|
|
|
$
|
7,919
|
|
|
$
|
43,918
|
|
|
$
|
33,582
|
|
|
Adjusted EBITDA(ii)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weston Foods
|
$
|
74
|
|
|
$
|
67
|
|
|
$
|
311
|
|
|
$
|
322
|
|
|
|
Loblaw
|
|
948
|
|
|
|
487
|
|
|
|
3,228
|
|
|
|
2,098
|
|
|
Total
|
$
|
1,022
|
|
|
$
|
554
|
|
|
$
|
3,539
|
|
|
$
|
2,420
|
|
|
Depreciation and Amortization(iii)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weston Foods
|
$
|
17
|
|
|
$
|
15
|
|
|
$
|
70
|
|
|
$
|
63
|
|
|
|
Loblaw
|
|
269
|
|
|
|
196
|
|
|
|
1,055
|
|
|
|
824
|
|
|
Total
|
$
|
286
|
|
|
$
|
211
|
|
|
$
|
1,125
|
|
|
$
|
887
|
|
|
Adjusted Operating Income(ii)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weston Foods
|
$
|
57
|
|
|
$
|
52
|
|
|
$
|
241
|
|
|
$
|
259
|
|
|
|
Loblaw
|
|
679
|
|
|
|
291
|
|
|
|
2,173
|
|
|
|
1,274
|
|
|
|
Impact of certain items(iv)
|
|
(157)
|
|
|
|
(9)
|
|
|
|
(1,529)
|
|
|
|
8
|
|
|
|
Other(v)
|
|
43
|
|
|
|
42
|
|
|
|
88
|
|
|
|
75
|
|
|
Consolidated operating income
|
$
|
622
|
|
|
$
|
376
|
|
|
$
|
973
|
|
|
$
|
1,616
|
|
|
Net Interest Expense and Other Financing Charges
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weston Foods
|
$
|
72
|
|
|
$
|
(21)
|
|
|
$
|
250
|
|
|
$
|
54
|
|
|
|
Loblaw
|
|
169
|
|
|
|
141
|
|
|
|
584
|
|
|
|
458
|
|
|
|
Other(vi)
|
|
(4)
|
|
|
|
(3)
|
|
|
|
(14)
|
|
|
|
(6)
|
|
|
|
Intersegment(vii)
|
|
(6)
|
|
|
|
(11)
|
|
|
|
(5)
|
|
|
|
(9)
|
|
|
Consolidated net interest expense and other financing charges
|
$
|
231
|
|
|
$
|
106
|
|
|
$
|
815
|
|
|
$
|
497
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i)
|
Certain 2013 figures have been amended. See note 2 of the Company's
consolidated financial statements included in the 2014 Annual Report.
|
(ii)
|
Excludes certain items and is used internally by management when
analyzing segment underlying operating performance.
|
(iii)
|
Excludes $124 million (2013 - nil) and $417 million (2013 - nil),
respectively, of amortization of intangible assets acquired with
Shoppers Drug Mart recorded by Loblaw in the fourth quarter of 2014 and
year-to-date, and accelerated depreciation $1 million and $4 million,
respectively, incurred in the fourth quarter of 2013 and year-to-date
by Weston Foods, included in restructuring and other charges.
|
(iv)
|
The impact of certain items excluded by management includes
restructuring and other charges, the fair value adjustment of
derivatives, fixed asset and other related impairments at Loblaw net of
recoveries, net insurance proceeds received by Weston Foods, the MEPP
settlement payment and withdrawal liability by Weston Foods,
restructuring of franchise fees at Loblaw, the fair value adjustment of
Shoppers Drug Mart's share-based compensation liability, certain costs
relating to Choice Properties, certain costs and charges and
divestiture loss relating to the acquisition of Shoppers Drug Mart, a
charge related to the change in inventory valuation methodology at
Loblaw, and defined benefit plan amendments.
|
(v)
|
Represents the effect of foreign currency translation on a portion of
the U.S. dollar denominated cash and short term investments held by
foreign operations.
|
(vi)
|
Represents the Trust Unit distributions from Choice Properties to GWL.
|
(vii)
|
Represents the elimination of the fair value adjustment of the Trust
Unit liability related to GWL's direct investment in Choice Properties.
|
2014 ANNUAL AUDITED CONSOLIDATED FINANCIAL STATEMENTS AND MANAGEMENT'S
DISCUSSION AND ANALYSIS
The Company's annual audited consolidated financial statements and MD&A
for the year ended December 31, 2014 are available in the Investor
Centre section of the Company's website at www.weston.ca and have been filed with SEDAR and are available online at www.sedar.com.
INVESTOR RELATIONS
Shareholders, security analysts and investment professionals should
direct their requests to Mr. Geoffrey H. Wilson, Senior Vice President,
Investor Relations, Business Intelligence and Communications, at the
Company's Executive Office or by e-mail at investor@weston.ca.
Additional financial information has been filed electronically with the
Canadian securities regulatory authorities in Canada through SEDAR.
This News Release includes selected information on Loblaw Companies
Limited, a public company with shares trading on the Toronto Stock
Exchange. For information regarding Loblaw, readers should also refer
to the materials filed by Loblaw with SEDAR from time to time. These
filings are also maintained at Loblaw's corporate website at www.loblaw.ca.
CONFERENCE CALL AND WEBCAST PRESENTATION
George Weston Limited will host a conference call as well as an audio
webcast on Thursday, March 5, 2015 at 11:00 a.m. (EST). To access via
tele-conference, please dial (647) 427-7450. The playback will be
available two hours after the event at (416) 849-0833, passcode:
66842681#. To access via audio webcast, please visit the Investor
Centre section of www.weston.ca. Pre-registration will be available.
|
|
|
|
Footnote Legend
|
|
|
(1)
|
See non-GAAP financial measures.
|
(2)
|
This News Release contains forward-looking information. See
Forward-Looking Statements of this News Release for a discussion of
material factors that could cause actual results to differ materially
from the forecasts and projections herein and of the material factors,
estimates, beliefs and assumptions that were applied in presenting the
conclusions, forecasts and projections presented herein. This News
Release must be read in conjunction with GWL's filings with securities
regulators made from time to time, all of which can be found at
www.weston.ca and www.sedar.com.
|
(3)
|
Certain 2013 figures have been amended. See the "Non-GAAP Financial
Measures" section of this News Release and note 2 of the Company's
consolidated financial statements included in the 2014 Annual Report.
|
|
|
SOURCE George Weston Limited
Geoffrey H. Wilson,
Senior Vice President, Investor Relations,
Business Intelligence and Communications
(416) 922-2500